Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II evaluation of gemtuzumab ozogamicin in combination with cytarabine in untreated patients above the age of 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome

Trial Profile

Phase II evaluation of gemtuzumab ozogamicin in combination with cytarabine in untreated patients above the age of 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2013

At a glance

  • Drugs Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2006 Status change
    • 25 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top